Puspitasari Yustina M, Ministrini Stefano, Schwarz Lena, Karch Caroline, Liberale Luca, Camici Giovanni G
Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
Internal Medicine, Angiology and Atherosclerosis, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Front Cell Dev Biol. 2022 May 18;10:882211. doi: 10.3389/fcell.2022.882211. eCollection 2022.
The improvements in healthcare services and quality of life result in a longer life expectancy and a higher number of aged individuals, who are inevitably affected by age-associated cardiovascular (CV) diseases. This challenging demographic shift calls for a greater effort to unravel the molecular mechanisms underlying age-related CV diseases to identify new therapeutic targets to cope with the ongoing aging "pandemic". Essential for protection against external pathogens and intrinsic degenerative processes, the inflammatory response becomes dysregulated with aging, leading to a persistent state of low-grade inflammation known as inflamm-aging. Of interest, inflammation has been recently recognized as a key factor in the pathogenesis of CV diseases, suggesting inflamm-aging as a possible driver of age-related CV afflictions and a plausible therapeutic target in this context. This review discusses the molecular pathways underlying inflamm-aging and their involvement in CV disease. Moreover, the potential of several anti-inflammatory approaches in this context is also reviewed.
医疗保健服务的改善和生活质量的提高导致预期寿命延长，老年人口数量增加，而这些老年人不可避免地会受到与年龄相关的心血管疾病的影响。这种具有挑战性的人口结构变化要求付出更大努力来揭示与年龄相关的心血管疾病背后的分子机制，以确定新的治疗靶点，应对持续的老龄化“大流行”。炎症反应对于抵御外部病原体和内在退行性过程至关重要，但随着年龄增长会失调，导致一种称为炎症衰老的低度炎症持续状态。有趣的是，炎症最近被认为是心血管疾病发病机制中的一个关键因素，这表明炎症衰老可能是与年龄相关的心血管疾病的驱动因素，也是这方面一个合理的治疗靶点。本综述讨论了炎症衰老背后的分子途径及其在心血管疾病中的作用。此外，还综述了几种在这种情况下的抗炎方法的潜力。
